Research graph
References from A phase 2 study of venetoclax plus azacitidine as induction therapy in fit middle-aged patients with newly diagnosed acute myeloid leukemia. Local targets link to admitted publications; unresolved targets remain external evidence.
Acute myeloid leukaemia
10.1016/s0140-6736(23)00108-3 · 2023 · External reference
Mortality and premature life lost from leukemia in China, 2005-2020: A study based on the National Mortality Surveillance System
10.1097/cm9.0000000000003946 · 2026 · External reference
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
10.1182/blood.2024027217 · 2025 · External reference
Venetoclax with decitabine as frontline treatment in younger adults with newly diagnosed ELN adverse-risk AML
10.1182/blood.2023020102 · 2023 · External reference
Venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia patients with RUNX1::RUNX1T1: A retrospective propensity score matching study
10.1038/s41408-023-00948-x · 2023 · External reference
